LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study

Launched by GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO · Nov 6, 2020

Keywords

ClinConnect Summary

This clinical trial is studying Langerhans Cell Histiocytosis (LCH) in adults, a rare condition where certain immune cells build up in the body, potentially causing various health issues. The trial aims to gather information from adult patients diagnosed with LCH from January 2001 onward, to understand how effective the first-line treatments are. Researchers will collect data about patients at the time of their diagnosis and during follow-ups over the next year after the last patient joins the study.

To participate, individuals must be at least 18 years old and have a confirmed diagnosis of LCH, verified through specific tests. The study is currently recruiting participants of any gender. By joining, patients will contribute valuable information that could help improve treatment options for others with this condition. It's important to note that only those with a confirmed diagnosis of LCH are eligible; those with other similar conditions will not be included.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed histological and immunohistochemical diagnosis of LCH (CD1a+, S-100+, CD207+), from January 2001 up to two years after the first enrolled patient. Patients with isolated vertebra plana, not related to a malignancy, and without a soft tissue component, are included without a histological and immunohistochemical diagnosis;
• • Age ≥18 years at the time of definitive diagnosis;
• • Signed, written informed consent, according to ICH/EU/GCP, and national, local laws.
• Exclusion Criteria:
• • Age ≥18 years and presumptive diagnosis of LCH, or definitive diagnosis of non-Langerhans Histiocytosis (Juvenile xantogranuloma, Rosai-Dorfman disease, Erdheim-Chester disease, etc.).